Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Elliot Cohen

Rheumatology Delray Beach, FL Medical Doctor

NPI 1942494810 CMS profile 223969

15300 S Jog Rd, 108, Delray Beach, FL 33446

Open in the dashboard

General payments

$350

6 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Elliot Cohen of Delray Beach, FL is reported in the CMS Open Payments database as having received $350 across 6 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 24th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $224 4
2021 General $16 1
2019 General $110 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elliot Cohen
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Elliot Cohen were reported at $0. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Elliot Cohen Rheumatology median Middle half National median
2019 $110 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $16 $531 $101–$2,153 $132
2022 $0 $627 $125–$2,303 $149
2023 $224 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $0 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Genzyme Corporation $148 1 payment
  2. Pfizer Inc. $110 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $36 1 payment
  4. Horizon Therapeutics plc $22 1 payment
  5. Novartis Pharmaceuticals Corporation $18 1 payment
  6. DePuy Synthes Sales Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $350 6 payments
Products named General payments · program years 2019–2023
  1. XELJANZ $110 1 payment
  2. OFEV $36 1 payment
  3. KRYSTEXXA $22 1 payment
  4. COSENTYX $18 1 payment
  5. ORTHOVISC $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

292

Median for Rheumatology: 1,511

Drug cost

$5,193

Median for Rheumatology: $1,139,948

Branded share of claims

21.6%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Risedronate Sodium Generic 16 $1,609
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $528
Methotrexate Methotrexate Sodium Brand 31 $411
Celecoxib Generic 25 $374
Gabapentin Generic 29 $364
Duloxetine Hcl Generic 27 $340
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 13 $338
Zolpidem Tartrate Generic 15 $317
Alendronate Sodium Generic 29 $239
Prednisone Generic 27 $170

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$9,495

Of which drugs: $47

Medicare patients

37

Average age 77

Services billed

389

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Depression 43%
Osteoporosis 41%
Ischemic heart disease 35%
Alzheimer's or dementia 0%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 260 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

6 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record